APRINOIA Therapeutics has completed Series C financing with a total amount of $40 million USD in 2021. The financing was led by Yantai Dongcheng Pharmaceutical Group and syndicated by current shareholders KTB Network, IMM, and TaiAn Technologies and several new investors, including Harvest Capital, a fund established by the Management Committee of Suzhou Industrial Park (SIP).
The new funding will support APRINOIA to further progress our pipeline, including completion of Phase 3 clinical trial for tau diagnostic PET tracer, 18F-APN-1607 and its commercial launch in China; further clinical development of 18F-APN-1607 globally and implementation of 18F-APN-1607 into our expanding global clinical networks; initiation of clinical studies for new PET tracers for movement disorders and our first tau therapeutic antibody, APN-mAb005; and expansion of our protein degradation platform aiming to clear abnormal protein aggregates in degenerating brains.